Stock Details
LLY is Eli Lilly and Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 313.91$. Average daily volumn in 3 months 2.75M. Market cap 315.21B



Stock symbol : LLY. Exchange : NYSE. Currency : USD
Lastest price : 329.89$. Total volume : 2.30M. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

Eli Lilly and Company (LLY)
Last Price
329.89$
Change
8.34
Volume
2.30M

Previous Close321.55
Open322.18
Day Range321.78-330.10
Bid0.00 x 900
Ask0.00 x 1.1k
Volume2.3M
Average Volume2.75M
Market Cap315.21B
Beta0.38
52 Week Range226.05-341.70
Trailing P/E52.61
Foward P/E34.22
Dividend (Yield %)1.22%
Ex-Dividend Date2022-08-12



Financial Details


According to Eli Lilly and Company's financial reports the company's revenue in 2021 were 28.32B an increase( +16.67%) over the years 2020 revenue that were of 24.54B. In 2021 the company's total earnings were 5.58B while total earnings in 2020 were 6.19B(-16.67%).


Loading ...



Organization

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramz... a for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

eli-lilly-and-company-logo

Market Cap:
315.21B
Revenue:
28.32B
Total Assets:
48.81B
Total Cash:
3.82B


News about "Eli Lilly and Company"

eli-lilly-loses-bid-to-cancel-teva-migraine-drug-patents-before-emgality-trial-image

Eli Lilly loses bid to cancel Teva migraine-drug patents before Emgality trial

Source from : Reuters - 16 hours ago

A Boston federal judge on Monday rejected Eli Lilly & Co's request to invalidate three Teva Pharmaceuticals International GmbH patents in a long-running legal battle over the companies' competing ...See details»


Eli Lilly and Company (NYSE: LLY)

Source from : The Motley Fool - 21 hours ago

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases.See details»


Eli Lilly and Company News

Source from : TheStreet.com - 7 days ago

Biogen and Eisai announced a positive surprise for a closely-watched Alzheimer's drug candidate in a late-stage study. Stocks finished little changed as investors assessed additional earnings ...See details»


eli-lilly-sued-for-age-discrimination-by-us-agency-eeoc-image

Eli Lilly sued for age discrimination by U.S. agency EEOC

Source from : Yahoo - 8 days ago

Eli Lilly and Co was sued on Monday by the U.S. Equal Employment Opportunity Commission, which accused the drugmaker of illegally refusing to hire older workers for sales representative jobs because ...See details»


is-eli-lilly-stock-a-buy-following-this-competitors-major-win-image

Is Eli Lilly Stock a Buy Following This Competitor's Major Win?

Source from : Nasdaq - 1 days ago

Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too. Still, a 7% jump for a company the size of Eli Lilly is huge. Was it justified? Here's ...See details»


Eli Lilly, EQT, Cash Cows ETF, Northrop Grumman And This Diagnostics Company Feature On CNBC's Final Trade

Source from : Benzinga.com on MSN - 1 days ago

On CNBCโ€™s โ€œHalftime Report Final Trades,โ€ Bryn Talkington of Requisite Capital Management said Pacer US Cash Cows 100 ETF (BATS: COWZ) is โ€œa factor-b ...See details»


Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Source from : Zacks.com on MSN - 1 days ago

Eli Lilly (LLY) closed the most recent trading day at $321.55, moving -0.56% from the previous trading session. This change lagged the S&P 500's daily gain of 2.59%. Elsewhere, the Dow gained 2.66%, ...See details»


is-eli-lilly-and-companys-nyselly-66-roe-better-than-average-image

Is Eli Lilly and Company's (NYSE:LLY) 66% ROE Better Than Average?

Source from : currently.att - 14 days ago

While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...See details»


Lilly is accused by the federal government of discriminating against older sales reps

Source from : STAT - 6 days ago

In an unusual move, the U.S. Equal Employment Opportunity Commission has filed a lawsuit accusing Eli ... Lilly human resources executive made a presentation in April 2017 that indicated the ...See details»


eli-lilly-lly-gets-fda-nod-for-ret-inhibitor-in-solid-tumors-image

Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors

Source from : Zacks.com on MSN - 12 days ago

Eli Lilly LLY announced that the FDA granted accelerated approval to Retevmo (selpercatinib) in adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection ...See details»


Biogen shares rally as Alzheimer's drug results show promise

Source from : CBS News - 6 days ago

The company is already seeking an accelerated ... which is what Aduhelm targets. Eli Lilly and Co. also is developing a potential treatment, donanemab, that helps clear the protein.See details»


The Next Frontier of Alzheimerโ€™s Disease Diagnosis and Treatment

Source from : The Atlantic - 5 days ago

ยน Anne White, senior vice president of pharmaceutical company Eli Lilly and Company and president of Lilly Neuroscience, has made it her personal mission to pursue innovation for patients and ...See details»


FDA Approves Lilly's Retevmoยฎ (selpercatinib...

Source from : Benzinga.com - 13 days ago

21, 2022 /PRNewswire/ -- Eli Lilly and Company LLY today announced the U.S. Food and Drug Administration (FDA) has granted approval to Retevmo ยฎ (selpercatinib, 40 mg & 80 mg capsules ...See details»


Lilly Announces Details of Presentations at ESMO Congress 2022

Source from : Business Insider - 27 days ago

INDIANAPOLIS, Sept. 7, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio ยฎ (abemaciclib) and Retevmo ยฎ (selpercatinib) will be presented ...See details»